NAA Services for Anti-Lupus Anticoagulants (LA)
Creative Biolabs is a leading service provider that focuses on antibody products and research, including natural autoantibodies (NAA). After years of efforts and investigations, we have successfully established a universal NAA platform to provide fast and professional services for our worldwide customers. At present, we are able to provide a full range of anti-lupus anticoagulants (LA) marker services for diseases diagnosis and therapeutic monitoring. Our professional team is optimized to help you get a milestone development in your NAA project.
Background of Lupus Anticoagulants (LA)
Lupus anticoagulant (LA), also known as lupus antibody, is a class of heterogeneous immunoglobulins binding to phospholipids, which was first described and isolated from patients with systemic lupus erythematosus as early as 1952. LAs actually are autoantibodies produced by the immune system that mistakenly attack healthy cells and proteins of body-self, specifically, target anionic phospholipids or phospholipids, so they belong to antiphospholipid antibodies family. LAs are mostly IgG type rarely IgM directly against proteins such as β2-glycoprotein I, prothrombin, or other proteins associated with the cell membrane and prolong phospholipid-dependent coagulation tests. Lupus anticoagulant antibodies in circulating systems induce an increase in inappropriate blood clotting or excess blood clot formation and interfere with phospholipids used to induce in vitro coagulation.
Fig.1 Lupus anticoagulant (LAC) activity. (Hoxha, 2017)
The Role of Anti-Lupus Anticoagulants (LA) in Immune Thrombocytopenia Purpura (ITP)
Immune thrombocytopenia purpura (ITP) is an autoimmune disorder of low platelet count with a bleeding tendency affecting the skin and mucosa. ITP usually results from autoantibody broad reactivity against platelet antigen causing premature immune destruction or increased clearance of platelets by the reticuloendothelial system, especially by splenic macrophages. Diagnosis of ITP includes complete blood count, together with other laboratory tests and exclusions. Notably, autoantibodies can be biomarkers that play key roles in the clinical diagnosis of ITP.
The presence of LAs has been demonstrated that could increase the risks of the ITP due to targeting the membrane of platelets. Moreover, ITP is a manifestation of primary antiphospholipid syndrome, which is strongly associated with antiphospholipid antibodies including LAs. Therefore, in addition to anti-platelet, LA may also serve as an indicator for ITP diagnosing.
Features of our Services about NAA
- Advantages in well-established technology platforms and experienced scientists specialized in NAA research
- One-stop NAA services, including but not limited to biomarker discovery, diagnosis development, autoantibody microarray, and custom services)
- High efficiency and high-quality solutions to meet every demand
- Best after-sale service
Creative Biolabs has the capability to provide a variety of NAA products and services. Our proven and optimized platforms can help you quickly get satisfactory results without repeated trials. Please contact us for more information and choose us to win success.
Reference:
- Hoxha, A.; et al. Detection of lupus anticoagulant in the era of direct oral anticoagulants. Autoimmunity Reviews. 2017, 16(2): 173-178.